Q-omics provides the consensus-scored CBX6 profile across patient tissues and cancer cell-line models. CBX6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CBX6 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CBX6 RNA expression shows 19,198 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, BLCA, and ACC as cancer lineages where CBX6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX6 survival associations across molecular data types. CBX6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX6 RNA expression–survival associations across cancer types. High CBX6 expression shows unfavorable associations in ACC and BLCA, but favorable associations in PAAD, LGG, KIRC and SCLC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for CBX6 RNA expression.
This table summarizes CBX6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CBX6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX6 shows lower tumor expression in BLCA, KICH, UCEC, LUAD and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher CBX6 RNA expression in normal versus tumor tissue (log2 FC = −2.300, t-test p < 0.001).
This table shows molecular features associated with CBX6 in patient tissues and cancer cell lines. In patient samples, CBX6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CBX6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
